Wildon Farwell, Chief Medical Officer of Dyne Therapeutics Inc (DYN, Financial), has sold 5,493 shares of the company on February 12, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $25.07 per share, which calculates to a total value of $137,679.51.
Dyne Therapeutics Inc is a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases. The company leverages its proprietary FORCE platform to enhance the delivery of therapeutics to muscle tissues.
Over the past year, the insider has sold a total of 19,105 shares of Dyne Therapeutics Inc and has not made any purchases of the stock. The recent sale by the insider is part of a series of transactions that have taken place over the last twelve months.
The insider transaction history for Dyne Therapeutics Inc shows a pattern of insider activity. There has been only 1 insider buy in the past year, contrasted with 40 insider sells during the same period, indicating a trend of insider sales.
On the day of the insider's recent sale, shares of Dyne Therapeutics Inc were trading at $25.07, giving the company a market capitalization of $1.961 billion.
Investors often monitor insider buying and selling as it can provide insights into a company's internal perspective. The ongoing selling activity by insiders at Dyne Therapeutics Inc may be of interest to shareholders and potential investors as they evaluate the company's stock performance and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
